Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Frederick L Locke

Showing results (51-60 of 234) with videos related to

Pageof 24
Sort By:
MDM Policy & Practice|June 27, 2025
A Cost-Effectiveness Analysis of Diffuse Large B-Cell Lymphoma Treatment Pathways in the United StatesAnik R Patel, Bradley Kievit, Ken Hasegawa, et al.
American Journal of Hematology|July 26, 2021
Efficacy and safety of CD19-directed CAR-T cell therapies in patients with relapsed/refractory aggressive B-cell lymphomas: Observations from the JULIET, ZUMA-1, and TRANSCEND trialsJason R Westin, Marie José Kersten, Gilles Salles, et al.
Clinical Lymphoma, Myeloma & Leukemia|June 1, 2023
CAR T Cell Therapy for Post-Transplant Lymphoproliferative Disorder After Solid Organ Transplantation: A Safe and Feasible Therapy for an Orphan DiseaseUroosa Ibrahim, Claude Bassil, Julio C Chavez, et al.
Journal of Managed Care & Specialty Pharmacy|October 31, 2025
Health care resource utilization and costs of patients with diffuse large B-cell lymphoma receiving chimeric antigen receptor T-cell therapies across different settings of care: A real-world data analysisAnik R Patel, Ken Hasegawa, Shivani Pandya, et al.
Journal of Medical Economics|April 21, 2022
Cost-effectiveness of axicabtagene ciloleucel versus lisocabtagene maraleucel for adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy in the USOlalekan O Oluwole, Rongzhe Liu, Ibrahim Diakite, et al.
Frontiers in Immunology|October 13, 2022
CAR-T manufactured from frozen PBMC yield efficient function with prolonged <i>in vitro</i> productionJulieta Abraham-Miranda, Meghan Menges, Reginald Atkins, et al.
Leukemia Research|June 4, 2014
Genomic aberrations deletion 11q and deletion 17p independently predict for worse progression-free and overall survival after allogeneic hematopoietic cell transplantation for chronic lymphocytic leukemiaJulio C Chavez, Mohamed A Kharfan-Dabaja, Jongphil Kim, et al.
Frontiers in Immunology|March 6, 2023
Repeatability of metabolic tumor burden and lesion glycolysis between clinical readersJung W Choi, Erin A Dean, Hong Lu, et al.
Journal of Immunology (Baltimore, Md. : 1950)|February 24, 2016
Cutting Edge: Engineering Active IKKβ in T Cells Drives Tumor RejectionCésar Evaristo, Stefani Spranger, Sarah E Barnes, et al.
Blood Advances|April 10, 2020
Grading of neurological toxicity in patients treated with tisagenlecleucel in the JULIET trialRichard T Maziarz, Stephen J Schuster, Vadim V Romanov, et al.
Pageof 24

Showing results (51-60 of 234) with videos related to

Sort By:
Pageof 24
MDM Policy & Practice|June 27, 2025
A Cost-Effectiveness Analysis of Diffuse Large B-Cell Lymphoma Treatment Pathways in the United StatesAnik R Patel, Bradley Kievit, Ken Hasegawa, et al.
American Journal of Hematology|July 26, 2021
Efficacy and safety of CD19-directed CAR-T cell therapies in patients with relapsed/refractory aggressive B-cell lymphomas: Observations from the JULIET, ZUMA-1, and TRANSCEND trialsJason R Westin, Marie José Kersten, Gilles Salles, et al.
Clinical Lymphoma, Myeloma & Leukemia|June 1, 2023
CAR T Cell Therapy for Post-Transplant Lymphoproliferative Disorder After Solid Organ Transplantation: A Safe and Feasible Therapy for an Orphan DiseaseUroosa Ibrahim, Claude Bassil, Julio C Chavez, et al.
Journal of Managed Care & Specialty Pharmacy|October 31, 2025
Health care resource utilization and costs of patients with diffuse large B-cell lymphoma receiving chimeric antigen receptor T-cell therapies across different settings of care: A real-world data analysisAnik R Patel, Ken Hasegawa, Shivani Pandya, et al.
Journal of Medical Economics|April 21, 2022
Cost-effectiveness of axicabtagene ciloleucel versus lisocabtagene maraleucel for adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy in the USOlalekan O Oluwole, Rongzhe Liu, Ibrahim Diakite, et al.
Frontiers in Immunology|October 13, 2022
CAR-T manufactured from frozen PBMC yield efficient function with prolonged <i>in vitro</i> productionJulieta Abraham-Miranda, Meghan Menges, Reginald Atkins, et al.
Leukemia Research|June 4, 2014
Genomic aberrations deletion 11q and deletion 17p independently predict for worse progression-free and overall survival after allogeneic hematopoietic cell transplantation for chronic lymphocytic leukemiaJulio C Chavez, Mohamed A Kharfan-Dabaja, Jongphil Kim, et al.
Frontiers in Immunology|March 6, 2023
Repeatability of metabolic tumor burden and lesion glycolysis between clinical readersJung W Choi, Erin A Dean, Hong Lu, et al.
Journal of Immunology (Baltimore, Md. : 1950)|February 24, 2016
Cutting Edge: Engineering Active IKKβ in T Cells Drives Tumor RejectionCésar Evaristo, Stefani Spranger, Sarah E Barnes, et al.
Blood Advances|April 10, 2020
Grading of neurological toxicity in patients treated with tisagenlecleucel in the JULIET trialRichard T Maziarz, Stephen J Schuster, Vadim V Romanov, et al.
Pageof 24